26
|
Garassino M, Paz-Ares L, Hui R, Faivre-Finn C, Spira A, Planchard D, Ozguroglu M, Daniel D, Vicente D, Murakami S, Rydén A, Zhang Y, O’Brien C, Dennis P, Antonia S. Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz094.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
27
|
Vasquez YM, Setlem R, Murakami S, Kraus WL. Abstract P5-05-16: Role of estrogen receptor alpha acetylation in estrogen-dependent gene regulation in breast cancers. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-05-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Estrogens, such as 17β-estradiol (E2), act through estrogen receptor alpha (ERα), a ligand-regulated transcription factor that binds across the genome to promote enhancer formation and regulate gene expression. ERα is expressed in approximately 70% of breast cancers, where it regulates the transcription of genes involved in mitogenic and inflammatory pathways. We are exploring the the acetylation of ERα on lysines 266 and 268, a modification that enhances the DNA binding and transcriptional activities of ERα. ERα acetylation is catalyzed by the lysine acetyltransferases p300 and CBP in an E2- and steroid receptor coregulator (SRC)-dependent manner. Acetylation-dependent activation of ERα has potential implications in breast cancers associated with enhanced coregulator interactions, such as SRC-3/Amplified in Breast (AIB1) gene amplifications and gain-of-function ERα mutations in endocrine resistant metastatic tumors, such as Y537S and D538G. Increased association of ERα with SRCs and p300/CBP leading to enhanced ERα acetylation may promote gain-of-function ERα activity. Our hypothesis is that acetylation of ERα alters its function by increasing E2-responsive gene transcription and signaling in breast cancers. Our current efforts are focused on investigating the role of ERα acetylation on chromatin binding and accessibility, enhancer activity, and target gene transcription. We are using the ER-positive MCF-7 breast cancer cell line with a knockdown/re-expression strategy with biochemical mimics of acetylated (K266/268Q) or unacetylated (K266/268R) ERα. Genomic ERα binding profiles using chromatin immunoprecipitation-sequencing (ChIP-seq) has defined overlapping, but unique, sets of transcriptional targets and recruitment kinetics for the ERα mutants. Current efforts are focused on defining global transcriptional responses associated with the unique binding activities using precision run-on sequencing (PRO-seq). Ultimately, our goal is to define how acetylation affects the binding of ERα to chromatin and its effect on the transcriptional activity of E2-target genes in breast cancers in the context of gain-of-function ERα mutations and coregulator amplifications. Supported in part by a postdoctoral fellowship from the Lalor Foundation to YMV, and grants from the NIDDK, NICHD, and CPRIT to WLK, as well as support from the Cecil H. and Ida Green Center for Reproductive Biology Sciences Endowment.
Citation Format: Vasquez YM, Setlem R, Murakami S, Kraus WL. Role of estrogen receptor alpha acetylation in estrogen-dependent gene regulation in breast cancers [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-05-16.
Collapse
|
28
|
Raben D, Faivre-Finn C, Spigel D, Daniel D, Villegas A, Vincente D, Hui R, de Castro Carpeno J, Murakami S, Paz-Ares L, Özgüroğlu M, Kurata T, Chiappori A, Lee K, de Wit M, Poole L, Wadsworth C, Dennis P, Antonia S. PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.08.057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
29
|
Mizuno T, Horinouchi H, Watanabe S, Sato J, Morita R, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. OA04 Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After First-Line EGFR-TKIs. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
30
|
Jo H, Horinouchi H, Higashiyama R, Tamura N, Yagishita S, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. P023 Factors Associated With Administration of Subsequent Cytotoxic Chemotherapy after Nivolumab in Patients With Advanced NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
31
|
Watanabe J, Horinouchi H, Shinno Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Nakamura Y, Watanabe S, Ohe Y. P050 Long-Term Survival of Stage IIIA-N2 NSCLC Patients with Interstitial Lung Diseases. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Makihara R, Narita S, Yamamoto N, Sato J, Murakami S, Goto Y, Kanda S, Fujiwara Y, Horinouchi H, Tsukamoto T, Hashimoto H, Makino Y, Ohe Y, Yamaguchi M. Relationships between lenvatinib plasma concentration and toxicity in Japanese cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy430.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Damiani C, Palmer J, Takeda N, Annino C, Balagué S, Bates P, Bernal S, Cornellá J, Dubus G, Esqué S, Gonzalez C, Ilkei T, Lewczanin M, Locke D, Mont L, Perrier B, Puiu A, Ruiz E, Shuff R, Van De Ven N, Van Hille C, Van Uffelen M, Choi C, Friconneau J, Hamilton D, Martin J, Murakami S, Reichle R, Cuevas JS, Maruyama T, Noguchi Y, Saito M. Overview of the ITER remote maintenance design and of the development activities in Europe. FUSION ENGINEERING AND DESIGN 2018. [DOI: 10.1016/j.fusengdes.2018.04.085] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Shinno Y, Kanda S, Sato J, Morita R, Matsumoto Y, Murakami S, Goto Y, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y. Clinical courses of patients with small cell lung cancer after complete resection followed by adjuvant chemotherapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy445.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Murakami S. COMPARATIVE BIOLOGICAL ANALYSIS OF DEMENTIA RISK FACTOR GENES FOR HUMANS AND CAENORHABDITIS ELEGANS. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Shibaki R, Murakami S, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Ohe Y. Association of immune-related pneumonitis with the phenotypic appearance of concurrent ILD in patients treated with anti-PD-1 antibody. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Takeyasu Y, Goto Y, Morita R, Sato J, Murakami S, Horinouchi H, Fujiwara Y, Kanda S, Yamamoto N, Ohe Y. Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy425.030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Spigel D, Vansteenkiste J, Reck M, Wakelee H, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Poole L, Wadsworth C, Dennis P, Antonia S. P1.16-05 Effect of Induction Chemotherapy in the PACIFIC Study. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.974] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
39
|
Hojo M, Kobayashi N, Hasegawa Y, Sakamoto Y, Murakami S, Yamamoto Y, Tada Y, Maeno A, Kubo Y, Ando H, Shimizu M, Taquahashi Y, Suzuki T, Nakae D, Hirose A. Relationship between developmental toxicity of multi-wall carbon nanotubes and lung inflammation in pregnant mice after repeated intratracheal instillation. Toxicol Lett 2018. [DOI: 10.1016/j.toxlet.2018.06.915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
40
|
Horinouchi H, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Nakayama Y, Ohe Y. Optimal interval from preceding radiotherapy (RT) to enhance efficacy of immune check point inhibitors (ICIs): Consecutive analysis of 294 patients with non-small cell lung cancer (NSCLC). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Faivre-Finn C, Spigel D, Senan S, Langer C, Raben D, Perez B, Özgüroğlu M, Daniel D, Villegas A, Vicente D, Hui R, Murakami S, Paz-Ares L, Poole L, Wadsworth C, Dennis P, Antonia S. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy291] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee K, De Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim Y, Karapetis C, Hiret S, Ostoros G, Kubota K, Gray J, Paz-Ares L, De Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel D, Wadsworth C, Taboada M, Dennis P, Özgüroğlu M. PL02.01 Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.010] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
43
|
Socinski M, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Gray J, Park K, Vincent M, Perrone F, Poole L, Wadsworth C, Dennis P, Antonia S. P1.16-04 Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.973] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
44
|
Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Rydén A, Zhang Y, Dennis P, Antonia S. 233O Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes. J Thorac Oncol 2018. [DOI: 10.1016/s1556-0864(18)30401-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Murakami S, Ijima H, Ono T, Kawakami K. Development of Co-Culture System of Hepatocytes with Bone Marrow Cells for Expression and Maintenance of Hepatic Functions. Int J Artif Organs 2018; 27:118-26. [PMID: 15061474 DOI: 10.1177/039139880402700207] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
In this study, a co-culture system of hepatocytes and bone marrow cells (BMCs) was developed and characterized for the expression and maintenance of ammonia metabolism and albumin secretion activities. A culture medium supplemented with epidermal growth factor, insulin, L-proline, hydrocortisone and 20 % (v/v) heat-inactivated fetal bovine serum was developed. In addition to adhesive bone marrow cells, the co-existence of non-adhesive bone marrow cells was effective in expressing liver-specific functions for at least 3 weeks. On the other hand, experiments with Transwell in which cultured cells were separated by a semi-permeable membrane, suggested that soluble factors secreted by BMCs are the key components in the functional enhancement of cells. Furthermore, direct contact between hepatocytes and BMCs enhanced the formation of spheroids and the expression of liver specific functions. These results indicate that this co-culture system is promising in, for example, bioartificial liver, regenerative medicine, and liver function simulator applications.
Collapse
|
46
|
Antonia S, Villegas A, Daniel D, Baz DV, Murakami S, Hui R, Yokoi T, Chiappori A, Lee K, de Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Jiang H, Huang Y, Dennis P, Özgüroğlu M. PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non–Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Tamura N, Horinouchi H, Sekine K, Matsumoto Y, Murakami S, Goto Y, Kanda S, Fujiwara Y, Yamamoto N, Ohe Y. Efficacy of subsequent cytotoxic chemotherapy after nivolumab for patients with advanced non-small cell lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx671.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Hui R, Özgüroğlu M, Daniel D, Baz D, Murakami S, Yokoi T, Chiappori A, Lee K, De Wit M, Cho BC, Gray J, Rydén A, Viviers L, Poole L, Dennis P, Antonia S. PL 02.02 Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.096] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Murakami S, Özgüroğlu M, Villegas A, Daniel D, Baz D, Hui R, Yokoi T, Chiappori A, Lee K, de Wit M, Cho B, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Jiang H, Huang Y, Dennis P, Antonia S. PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
50
|
Okada A, Choh S, Nakai T, Ohbayashi C, Kurono Y, Ueda M, Katayama K, Koguchi N, Murakami S, Takenaka H. P2.01-065 Clinico-Radiological and Pathological Evaluation of Lung Adenocarcinoma with Infiltration on the Computed Tomography of the Chest. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|